#USA #Hamilton #Actinium-225 #AtomVie #TerraPower Isotopes

Strategic Partnership to Enhance Cancer Treatment

In an important development for the field of nuclear medicine, AtomVie Global Radiopharma (AtomVie) has inked a strategic supply agreement with TerraPower Isotopes, LLC (TPI) to provide Actinium-225 (Ac-225) isotopes. This collaboration aims to bolster AtomVie’s capabilities in radiopharmaceutical development and manufacturing, ultimately improving treatment options for cancer patients. The supply of high-quality Ac-225 will play a vital role in enhancing the drug development lifecycle for AtomVie, allowing them to efficiently support both early and late-stage programs in partnership with pharmaceutical companies.

The recent agreement is not just a supply deal; it marks a critical step forward in the ongoing quest for innovative cancer therapies. By securing a reliable supply of Ac-225, AtomVie can ensure that they are well-equipped to meet the increasing demands of their global clinical and commercial projects. This initiative aligns with AtomVie’s mission of delivering state-of-the-art radiopharmaceuticals that target specific cancer cells while minimizing harm to surrounding healthy tissue.

Benefits for Patients and Pharmaceutical Partners

Bruno Paquin, CEO of AtomVie, expressed optimism about the partnership, stating, "We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply." Through this collaboration, AtomVie aims to advance its innovative therapies and improve patients' lives across the globe.

Supporting a Vision for Global Health

According to Scott Claunch, President of TerraPower Isotopes, their involvement in this initiative allows them to contribute to the next generation of targeted radiopharmaceutical therapies, emphasizing their high-quality Ac-225 production. Claunch noted, "By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients."

This collaboration not only reinforces the supply chain for Ac-225 but also reflects the shared commitment of both companies to enhance nuclear medicine innovation. By expanding access to these crucial isotopes, they are positioned to play a significant role in advancing the future of cancer treatment.

AtomVie and TerraPower Isotopes Overview

About AtomVie Global Radiopharma

AtomVie is a prominent Contract Development and Manufacturing Organization (CDMO) specializing in the good manufacturing practices (GMP) production and distribution of clinical and commercial radiopharmaceuticals. With a robust framework that combines scientific, technical, regulatory, quality, and logistical support, AtomVie is well-equipped to drive forward the development of radiopharmaceuticals from the fetal stages to the market. Currently, AtomVie is in the process of establishing a state-of-the-art facility in Hamilton, designed to enhance their operational capabilities by the end of 2025.

About TerraPower Isotopes

TerraPower Isotopes operates under the umbrella of TerraPower, a leading name in nuclear innovation. The company is at the forefront of developing advanced isotopes for medical applications, focusing on supporting impactful cancer research. Their mission is to improve patient outcomes by making life-saving isotopes like Ac-225 more widely available, ultimately pushing the boundaries of what is achievable in targeted alpha therapy.

Conclusion

In conclusion, the strategic agreement between AtomVie and TerraPower Isotopes is a promising initiative that holds the potential to reshape the landscape of cancer treatment. By streamlining the supply of Actinium-225, both companies not only strengthen their operational capacities but also champion a global health vision that prioritizes innovative, effective, and life-enhancing therapies for cancer patients worldwide.